These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 31585937)

  • 1. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
    Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L
    Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdafitinib for the treatment of urothelial cancer.
    Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
    Chiba Y; Sudo K; Kojima Y; Okuma H; Kohsaka S; Machida R; Ichimura M; Anjo K; Kurishita K; Okita N; Nakamura K; Kinoshita I; Takahashi M; Matsubara J; Kusaba H; Yonemori K; Takahashi M
    BMC Cancer; 2022 Aug; 22(1):869. PubMed ID: 35945547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
    Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
    Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptors as treatment targets in clinical oncology.
    Katoh M
    Nat Rev Clin Oncol; 2019 Feb; 16(2):105-122. PubMed ID: 30367139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
    Krook MA; Reeser JW; Ernst G; Barker H; Wilberding M; Li G; Chen HZ; Roychowdhury S
    Br J Cancer; 2021 Mar; 124(5):880-892. PubMed ID: 33268819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Chandana SR; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
    De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
    Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
    Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas.
    Wekking D; Pretta A; Martella S; D'Agata AP; Joeun Choe J; Denaro N; Solinas C; Scartozzi M
    Heliyon; 2023 Sep; 9(9):e19541. PubMed ID: 37681152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.